Beech Hill Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$659K Sell
5,160
-235
-4% -$29.3K 0.33% 71
2025
Q4
$658K Sell
5,395
-360
-6% -$41.3K 0.31% 71
2025
Q3
$577K Sell
5,755
-496
-8% -$44.7K 0.27% 75
2025
Q2
$518K Sell
6,251
-389
-6% -$31K 0.23% 78
2025
Q1
$539K Sell
6,640
-15
-0.2% -$1.34K 0.21% 80
2024
Q4
$599K Buy
6,655
+162
+2% +$15.7K 0.22% 78
2024
Q3
$642K Buy
6,493
+60
+0.9% +$5.89K 0.24% 75
2024
Q2
$596K Sell
6,433
-35
-0.5% -$3.14K 0.25% 74
2024
Q1
$614K Buy
6,468
+1,616
+33% +$150K 0.26% 69
2023
Q4
$433K Buy
+4,852
New +$360K 0.21% 75

Other funds holding XBI

Beech Hill Advisors's XBI Position: Q1 2026 in Review

Beech Hill Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 4.4% in Q1 2026, selling an estimated $29.3K and leaving 5,160 shares worth $659K. The position accounts for 0.33% of the portfolio, ranked #71.

Beech Hill Advisors first reported a position in XBI in Q4 2023 and has held it in 10 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Beech Hill Advisors held 5,160 shares of State Street SPDR S&P Biotech ETF worth $659K as of Q1 2026.
  • Beech Hill Advisors sold 235 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $29.3K.
  • State Street SPDR S&P Biotech ETF made up 0.33% of Beech Hill Advisors's portfolio in Q1 2026, its #71 holding.
  • Beech Hill Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 10 quarters since.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Beech Hill Advisors's 13F filing for Q1 2026, filed 9 Apr 2026.